Table 2 MS/MS-based phospholipid identification increased in breast cancer (600–850 m/z)

671.47

PA (16:0/18:2)

[M-H]-

PA (16:1/18:1)

[M-H]-

PE (16:1/16:0)

[M-NH₃-H]-

673.48

PA (16:0/18:1)

[M-H]-

PA (18:0/16:1)

[M-H]-

PE (16:0/16:0)

[M-NH₃-H]-

687.5

PA (P-20:0/16:0)

[M-H]-

PA (O-18:0/18:1)

[M-H]-

699.5

PE (16:0/18:1)

[M-NH₃-H]-

PA (18:1/18:1)

[M-H]-

PA (18:0/18:2)

[M-H]-

713.51

PA (P-20:0/18:1)

[M-H]-

PA (O-20:0/18:2)

[M-H]-

PG (P-16:0/18:1)

[M-H₂O-H]-

714.51

PE (16:0/18:2)

[M-H]-

PE (16:1/18:1)

[M-H]-

PE (16:2/18:0)

[M-H]-

716.52

PE (18:0/16:1)

[M-H]-

PE (16:0/18:1)

[M-H]-

717.51

PA (O-16:0/20:4)

[M + Cl]-

PC (16:0/16:0)

[M-CH₃-H]-

735.47

PA (P-20:0/20:4)

[M-H]-

PA (P-20:1/20:3)

[M-H]-

PG (O-18:0/16:0)

[M-H]-

PA (18:0/18:2)

[M + Cl]-

PA (18:1/18:1)

[M + Cl]-

PA (P-18:0/22:4)

[M-H]-

742.54

PE (18:0/18:2)

[M-H]-

PE (18:1/18:1)

[M-H]-

PC (16:1/18:1)

[M-CH₃-H]-

PC (16:0/18:2)

[M-CH₃-H]-

744.55

PC (16:0/18:1)

[M-CH₃-H]-

PC (18:0/16:1)

[M-CH₃-H]-

PE (18:0/18:1)

[M-H]-

747.51

PA (18:1/22:5)

[M-H]-

PA (18:2/22:4)

[M-H]-

PE (18:1/20:4)

[M-NH₃-H]-

PE (16:0/22:5)

[M-NH₃-H]-

PE (18:0/20:5)

[M-NH₃-H]-

766.54

PS (P-16:0/20:4)

[M-H]-

PE (18:0/20:4)

[M-H]-

PC (16:0/20:4)

[M-CH₃-H]-

768.55

PC (18:1/18:2)

[M-CH₃-H]-

PC (16:0/20:3)

[M-CH₃-H]-

PE (20:2/18:1)

[M-H]-

PE (18:0/20:3)

[M-H]-

770.57

PE (18:0/20:2)

[M-H]-

PC (18:1/18:1)

[M-CH₃-H]-

PC (18:0/18:2)

[M-CH₃-H]-

772.58

PE (18:0/20:1)

[M-H]-

PC (18:0/18:1)

[M-CH₃-H]-

PS (O-18:0/18:2)

[M-H]-

PE (P-18:1/22:6)

[M-H]-

792.55

PC (16:0/18:2)

[M + Cl]-

PC (18:2/20:3)

[M-CH₃-H]-

PC (18:0/20:5)

[M-CH₃-H]-

PC (18:1/20:4)

[M-CH₃-H]-

PE (18:1/22:4)

[M-H]-

PE (18:0/22:5)

[M-H]-

794.57

PC (16:0/22:4)

[M-CH₃-H]-

PC (18:1/20:3)

[M-CH₃-H]-

PC (18:0/20:4)

[M-CH₃-H]-

PC (16:0/18:1)

[M + Cl]-